Arzoxifene Eli Lilly

Cristina Marchisano-Karpman, Michael W. DeGregorio

Research output: Contribution to journalArticle

2 Scopus citations


Arzoxifene is a benzothiophene second-generation selective estrogen receptor modulator (SERM) under development by Eli Lilly & Co as a potential treatment for cancer.

Original languageEnglish (US)
Pages (from-to)880-885
Number of pages6
Issue number9
StatePublished - Sep 1 2003

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Arzoxifene Eli Lilly'. Together they form a unique fingerprint.

  • Cite this

    Marchisano-Karpman, C., & DeGregorio, M. W. (2003). Arzoxifene Eli Lilly. IDrugs, 6(9), 880-885.